Chloroquine Phosphate
Brand Names: Aralen
Methodology & AI Transparency ⓘ
Chloroquine Phosphate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P.
- 2 Real-world patient consensus: Real-world cohort score of 75% across 19 de-identified Chloroquine Phosphate entries.
- 3 Typical cash cost range: Public pharmacy ledger: $56.75 low cash benchmark vs. $139.04 chain retail average ($5.7554/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Chloroquine Phosphate: nausea (8.6%), headache (7.1%), dizziness (5.1%).
Ask our AI Specialists anything about Chloroquine Phosphate
Chloroquine Phosphate Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P. malariae, P. ovale, and P. vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites.
CLINICAL PHARMACOLOGY Chloroquine is rapidly and almost completely absorbed from the gastrointestinal tract, and only a small proportion of the administered dose is found in the stools. Approximately 55% of the drug in the plasma is bound to nondiffusible plasma constituents. Excretion of chloroquine is quite slow but is increased by acidification of the urine. Chloroquine is deposited in the tissues in considerable amounts. In animals, from 200 to 700 times the plasma concentration may be found in the liver, spleen, kidney, and lung; leukocytes also concentrate the drug.
Following administration (500 mg/1 Tablet, Coated), Chloroquine Phosphate achieves Oral fraction absorbed ranges from 46% to 58% (Chloroquine Phosphate 500) bioavailability and oral tmax achieved within 2 to 4 hours following chloroquine phosphate ingestion onset, governed by a Mean elimination half-life of 4 to 8 hours across adult Chloroquine Phosphate dosing terminal half-life through dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of chloroquine phosphate.
Before initiating Chloroquine Phosphate at 500 mg/1 Tablet, Coated, clinical safety checklists rule out use of chloroquine phosphate tablets is contraindicated in patients with known hypersensitivity to 4- aminoquinoline compounds.; history of severe allergic sensitivity to chloroquine phosphate active moiety or formulation vehicle. Logged tolerability patterns center on nausea (8.6% of reports), headache (7.1% of reports), fatigue (5.4% of reports).
Verify medication reconciliation lists so Chloroquine Phosphate is not inadvertently duplicated with another antimalarial.
Botanical enzyme modulators may alter oral first-pass exposure of Chloroquine Phosphate; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Use of Chloroquine phosphate tablets is contraindicated in patients with known hypersensitivity to 4- aminoquinoline compounds.
- History of severe allergic sensitivity to Chloroquine Phosphate active moiety or formulation vehicle
Logged Side-Effect Incidence (19 Reports)
Chloroquine Phosphate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Chloroquine Phosphate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the Although the JOQUER trial reported no overall benefit from HCQ in pSS patients, stratification suggests that. Rheumatology international • 2021-09-15 • Phase III Randomized Trial | N = 32 | 88/100 | PMID 34165604 ↗ |
| New Insights on Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years: What a 300-Participant Study Found In this study, the sustained low prevalence of pfdhfr/dhps quintuple mutant justifies the continued use of SP- containing IPTp and PMC, as well as its expansion in the country into the second year of life with additional SP doses. Gates open research • 2025-01-15 • Phase III Randomized Trial | N = 300 | 87/100 | PMID 41080970 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Archives of virology • 2021-03-15 • Phase III Randomized Trial | N = 96 | 82/100 | PMID 33492523 ↗ |
| Can This Approach Help? Inside the Latest Research on Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: A total of 68 HCWs met the eligibility criteria were randomly allocated to receive HCQ (n = 36) or not (n = 32). BMC research notes • 2023-02-28 • Phase III Randomized Trial | N = 36 | 82/100 | PMID 36849996 ↗ |
| Can This Approach Help? Inside the Latest Research on An open-label randomized controlled trial evaluating the efficacy of In patients with severe COVID-19, the use of chloroquine/hydroxychloroquine added to standard treatment resulted in a significant worsening of clinical status, an increased risk of kidney dysfunction and an increased need for... Scientific reports • 2021-04-27 • Phase III Randomized Trial | N = 105 | 82/100 | PMID 33907251 ↗ |
Chloroquine Phosphate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $5.7554/unit (~$172.66/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $56.75 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $139.04 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $65.26 / mo | View logs ↓ |
Chloroquine Phosphate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Chloroquine Phosphate RxNorm Concept ID | 1116758 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $5.7554 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $139.04 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $56.75 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 75.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Chloroquine Phosphate Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Chloroquine Phosphate integrating DailyMed SPL (2025-12-10), CMS NADAC ($5.7554/unit), and 19 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Chloroquine Phosphate community threads and patient logs by age, biological sex, dosage, and treatment duration.